Literature DB >> 31090329

[Aconitine ameliorates cardiomyocyte hypertrophy induced by angiotensin Ⅱ].

Ning-Ning Wang1, Jia Wang1, Hong-Ling Tan2, Yu-Guang Wang2, Yue Gao1, Zeng-Chun Ma1.   

Abstract

This paper was aimed to investigate the inhibitory effect of aconitine(AC) on angiotensin Ⅱ(Ang Ⅱ)-induced H9 c2 cell hypertrophy and explore its mechanism of action. The model of hypertrophy was induced by Ang Ⅱ(1×10-6 mol·L-1),and cardiomyocytes were incubated with different concentrations of AC. Western blot was used to quantify the protein expression levels of atrial natriuretic peptide(ANP),brain natriuretic peptide(BNP),β-myosin heavy chain(β-MHC),and α-smooth muscle actin(α-SMA). Real-time quantitative PCR(qRT-PCR) was used to quantify the mRNA expression levels of cardiac hypertrophic markers ANP,BNP and β-MHC. In addition,the fluorescence intensity of the F-actin marker,an important component of myofibrils,was detected by using laser confocal microscope. AC could significantly reverse the increase of total protein content in H9 c2 cells induced by Ang Ⅱ; qRT-PCR results showed that AC could significantly inhibit the ANP,BNP and β-MHC mRNA up-regulation induced by AngⅡ. Western blot results showed that AC could significantly inhibit the ANP,BNP and β-MHC protein up-regulation induced by AngⅡ. In addition,F-actin expression induced by Ang Ⅱ could be inhibited by AC,and multiple indicators of cardiomyocyte hypertrophy induced by Ang Ⅱ could be down-regulated,indicating that AC may inhibit cardiac hypertrophy by inhibiting the expression of hypertrophic factors,providing new clues for exploring the cardiovascular protection of AC.

Entities:  

Keywords:  H9c2 cells; aconitine; angiotensin Ⅱ; cardiac hypertrophy

Mesh:

Substances:

Year:  2019        PMID: 31090329     DOI: 10.19540/j.cnki.cjcmm.20190117.002

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Tentative exploration of pharmacodynamic substances: Pharmacological effects, chemical compositions, and multi-components pharmacokinetic characteristics of ESZWD in CHF-HKYd rats.

Authors:  Li-Li Hong; Yan Zhao; Wei-Dong Chen; Chen-Yu Yang; Guo-Zhuan Li; Hong-Song Wang; Xiao-Yu Cheng
Journal:  Front Cardiovasc Med       Date:  2022-09-14

2.  Repeated Aconitine Treatment Induced the Remodeling of Mitochondrial Function via AMPK-OPA1-ATP5A1 Pathway.

Authors:  Li-Zhen Qiu; Wei Zhou; Lan-Xin Yue; Yi-Hao Wang; Fei-Ran Hao; Peng-Yan Li; Yue Gao
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.